Increased risk of Q151M and K65R mutations in patients failing stavudine-containing first-line antiretroviral therapy in Cambodia
about
Virological failure and HIV-1 drug resistance mutations among naive and antiretroviral pre-treated patients entering the ESTHER program of Calmette Hospital in CambodiaHIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in AsiaDrug susceptibility and resistance mutations after first-line failure in resource limited settingsAdvanced HIV Disease at Enrolment in HIV Care: Trends and Associated Factors over a Ten Year Period in CambodiaFactors associated with the failure of first and second-line antiretroviral therapies therapy, a case control study in Cambodian HIV-1 infected children.Comparison of genotypic and virtual phenotypic drug resistance interpretations with laboratory-based phenotypes among CRF01_AE and subtype B HIV-infected individualsDevelopment of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern.Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex That Confer Multinucleoside Drug Resistance.Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.
P2860
Q28542625-25BAEE18-DF3C-42EF-8B29-D3F4948CFA46Q34072721-A44060C7-BE69-4C35-9F2F-17578FC52654Q34106181-8F04C8D1-AF61-436D-954B-0D8A57B635CFQ35852326-A3852AD2-DE3F-478D-9339-196350CAB0ACQ35916294-B9F38112-4651-400A-B9B8-514919C0A2FCQ36422328-9E6FFF8A-3A0B-479F-884A-D4D025E2B0B4Q37461250-A661E9F5-0BDD-499E-A34C-6F0F21848509Q39142877-86D0E292-945B-4CE5-B90B-2C34CF6C55D7Q40249141-DDCF2EDF-BDA1-45C0-96B0-1048F83DA00DQ52319934-707975F2-9960-4CD9-9BD8-457C08C40CC9
P2860
Increased risk of Q151M and K65R mutations in patients failing stavudine-containing first-line antiretroviral therapy in Cambodia
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Increased risk of Q151M and K6 ...... retroviral therapy in Cambodia
@ast
Increased risk of Q151M and K6 ...... retroviral therapy in Cambodia
@en
Increased risk of Q151M and K6 ...... retroviral therapy in Cambodia
@nl
type
label
Increased risk of Q151M and K6 ...... retroviral therapy in Cambodia
@ast
Increased risk of Q151M and K6 ...... retroviral therapy in Cambodia
@en
Increased risk of Q151M and K6 ...... retroviral therapy in Cambodia
@nl
prefLabel
Increased risk of Q151M and K6 ...... retroviral therapy in Cambodia
@ast
Increased risk of Q151M and K6 ...... retroviral therapy in Cambodia
@en
Increased risk of Q151M and K6 ...... retroviral therapy in Cambodia
@nl
P2860
P50
P3181
P1433
P1476
Increased risk of Q151M and K6 ...... retroviral therapy in Cambodia
@en
P2093
Janin Nouhin
Laurent Ferradini
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0073744
P407
P577
2013-01-01T00:00:00Z